Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2017

View Archived Issues

PepVax initiates in vivo efficacy study for lead candidate PVX-009

Heptares initiates phase I study of selective muscarinic M4 receptor agonist HTL-0016878

Oncodesign acquires Bertin Pharma's pharmaceutical and biotech services business

EMD Serono details discovery of BTK inhibitor now in clinical development

Second-generation RET inhibitors developed for irritable bowel syndrome

EMBL, Savira patent compounds for treating influenza

MediWound reports new phase II data on EscharEx

Inventisbio describes new indoleamine 2,3-dioxygenase 1 inhibitors

High mobility group protein B1 inhibitors disclosed by Kyungpook National University

Global Blood Therapeutics divulges novel EHMT2 inhibitors

Sprint Bioscience discloses novel PIK3C3 and autophagy inhibitors

Protein kinase inhibitors reported at Korea Institute of Science and Technology, DGMIF

Debiopharm, Evotec describe new IDH1, IDH2 inhibitors

APRIL has prognostic significance in acute heart failure

Midatech submits CTA to begin first-in-human study of MTD-201

Spyryx Biosciences initiates phase II study of SPX-101 in cystic fibrosis

INN-108 receives U.S. orphan drug status for pediatric ulcerative colitis

U.S. Traumakine BLA submission can follow completion of European and Japanese phase III studies

FDA grants tentative approval to Sanofi's Admelog

FDA confers orphan drug status on VXM-01 for malignant glioma

Venetoclax given FDA orphan drug designation for mantle cell lymphoma

Collaboration discovers enhanced GABA(A) receptor subunit alpha-6 ligands

FDA approves Mylotarg for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...